Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART

Trial Profile

A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Vacc-4x (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Bionor Holding; Bionor Pharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
    • 13 Jun 2016 According to Bionor Pharma media release, Bionor had a collaboration with SCHARP since 2014 with the purpose of performing a post-hoc statistical analysis of data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top